Related content

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study

By  

Current Alzheimer Research, Vol. 15, Iss. 13, 2018-12 ,pp. : 1231-1243

Bentham Science Publishers

Access to resources Recommend Favorite

The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H3 Receptor Antagonist in Patients with Mild to Moderate Alzheimer's Disease: A Preliminary Investigation

By  

Current Alzheimer Research, Vol. 10, Iss. 3, 2013-03 ,pp. : 240-251

Bentham Science Publishers

Access to resources Recommend Favorite

Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics

By Kim Chang Yoon   Chung Seockhoon   Hahm Bong-Jin   Hong Kyung Sue   Yoon Jin-Sang   Kim Young-Hoon   Bahk Won-Myong   Lee Sang-Yeol   Lee Yanghyun   Chung In-Won   Kim Chan-Hyung  

International Journal of Psychiatry in Clinical Practice, Vol. 13, Iss. 3, 2009-09 ,pp. : 192-198

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial

By  

Current Alzheimer Research, Vol. 5, Iss. 1, 2008-02 ,pp. : 83-89

Bentham Science Publishers

Access to resources Recommend Favorite

Awareness of cognitive deficits and clinical competence in mild to moderate Alzheimer’s disease: their relevance in clinical practice

By Gambina G.   Bonazzi A.   Valbusa V.   Condoleo M.   Bortolami O.   Broggio E.   Sala F.   Moretto G.   Moro V.  

Neurological Sciences, Vol. 35, Iss. 3, 2014-03 ,pp. : 385-390

Springer Publishing Company

Access to resources Recommend Favorite